Published: 2021-09-23

An observational study on Awareness of Teratogenic drugs among Undergraduate Medical Students from two medical institutes of Central India

Devendra Singh Kushwah, Beenu Kushwah


Background: Teratogenicity caused by drugs can be avoided to major extent just by creating more awareness about rational use of drugs among treating doctors. Deleterious effects of a drug upon developing foetus are directly related with the stage of embryological development at the time of exposure. Attainment of right knowledge at right time about teratogenicity of a particular drug is very crucial which requires more awareness among general doctors in a country like India where most of the pregnant females are manged by these doctors only in peripheral regions. Present study was an observational study to assess basic knowledge of undergraduate medical students regarding teratogenicity in order to make necessary changes in existing mode of training of this particular topic.

Methods: Present study was a questionnaire based cross sectional observational study to assess basic knowledge of undergraduate medical students regarding different aspects of teratogenicity. It included 250 students of two medical colleges of central India.

Results: Out of 250 students 146 students reported on time. Maximum students (71%) were aware about the teratogenicity property of certain harmful drugs. Although 90% of students knew that early first trimester is the most susceptible time, only 21% could state the importance of doing counselling regarding use of drugs even before pregnancy.

Conclusions: Based on the findings of present study it is obvious that more emphasis should be put on improving knowledge about teratogenic drugs during early years of medical training in order to bring about necessary changes in existing practices of treating doctors.


Teratogenicity, Medical students, Congenital malformations

Full Text:



Rang HP, Dale MM, Ritter JM, Fowler RJ. The Harmful effects of drugs. Rang and Dale’s pharmacology. 6th ed. Edinburgh, UK: Churchill Livingstone; 2007: 757-758.

McBride WB. Thalidomide and congenital abnormalities. Lancet. 1961;21358.

Bisht M, Dhasmana DC. Teratagenecity and maternogenicity. Myths and facts. RJPBCS. 2014;5:452-69.

Clementi M, Gianantonio E, Ornoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet. 2002;5(1):8-12.

Webster WS, Freeman JA. Is this drug safe in pregnancy? Reprod Toxicol. 2001;15(6):619-29.

Koren G, Pastuszak A. Teratogen Information Service. Maternal fetal toxicology: a clinician's guide. 2nd ed. New York, NY: Marcel Dekker; 1994: 683-705.

Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol. 1997;78(2):183-6.

WHO. Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. 6th ed. Geneva: WHO; 2011.

Guttmacher Institute. Facts on abortion and unintended pregnancy in Asia. Available at: Accessed on 02 July 2021.

Bianca S. Drug use during pregnancy: are risk classifications more dangerous than the drugs?. Lancet. 2003;362(9380):329.

Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010;66(2):207-14.

Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398-407.

Sharma R. Birth defects in India: Hidden truth, need for urgent attention. Indian J Hum Genet. 2013;19(2):125-9.

Bánhidy F, Lowry RB, Czeizel AE. Risk and benefit of drug use during pregnancy. Int J Med Sci. 2005;2(3):100-6.

Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J Am Board Fam Med. 2007;20(3):289-98.

Yankowitz J, Niebyl JR. Drug Therapy in Pregnancy. 3rd ed. United States: Lippincott Williams & Wilkins; 2001.